Advertisement

Topics

GSK to evaluate Insilico’s AI technology to enhance drug discovery process.

05:27 EDT 17 Aug 2017 | Pharmaceutical Business Review

GlaxoSmithKline and Insilico Medicine are partnering to assess how the latter’s artificial intelligence (AI) technology can help in the drug discovery process.

Original Article: GSK to evaluate Insilico’s AI technology to enhance drug discovery process.

NEXT ARTICLE

More From BioPortfolio on "GSK to evaluate Insilico’s AI technology to enhance drug discovery process."

Quick Search
Advertisement
 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...